ArticleTheranostics2017
Liposomal Nanoparticles Carrying anti-IL6R Antibody to the Tumour Microenvironment Inhibit Metastasis in Two Molecular Subtypes of Breast Cancer Mouse Models.
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy.Frontiers in immunology · 2022Pooled it
- Adipocyte-derived IL6 and triple-negative breast cancer cell-derived CXCL1 co-activate STAT3/NF-κB pathway to mediate the crosstalk between adipocytes and triple-negative breast cancer cells.Cell death discovery · 2025Article
- Harnessing the Power of Nanocarriers to Exploit the Tumor Microenvironment for Enhanced Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- STAT3: Key targets of growth-promoting receptor positive breast cancer.Cancer cell international · 2024Review
- Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy.Nature communications · 2024Article
- Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges.International journal of nanomedicine · 2024Review
- Review
- Functionalized liposomes for targeted breast cancer drug delivery.Bioactive materials · 2023Review
- STAT3 pathway in cancers: Past, present, and future.MedComm · 2022Review
- Depletion of Mannose Receptor-Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice.Cancer research communications · 2022Article
- IL-6: The Link Between Inflammation, Immunity and Breast Cancer.Frontiers in oncology · 2022Review
- Multi‑faceted role of cancer‑associated adipocytes in the tumor microenvironment (Review).Molecular medicine reports · 2021Review
- Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer.Advanced drug delivery reviews · 2021Review
- Targeting Engineered Nanoparticles for Breast Cancer Therapy.Pharmaceutics · 2021Review
- IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.Theranostics · 2021Article
- Review
- Liposome-Based Drug Delivery Systems in Cancer Immunotherapy.Pharmaceutics · 2020Review
- A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy.Nano-micro letters · 2020Review
- Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer.Pharmaceutics · 2020Review
- Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients.ACS nano · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
Tumour microenvironment (TME) contributes significantly towards potentiating the stemness and metastasis properties of cancer cells. IL6-Stat3 is one of the important cell signaling pathways in mediating the communication between tumour and immune cells. Here, we have systematically developed a novel anti-CD44 antibody-mediated liposomal nanoparticle delivery system loaded with anti-IL6R antibody, which could specifically target the TME of CD44
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.